Sigyn Therapeutics, Inc. (RGNP) [Rocket]

Overview

Sigyn Therapeutics, Inc. (RGNP)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/04/2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/14/2023	10-Q	Quarterly Report for the period ended June 30, 2023
07/07/2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
06/08/2023	8-K	Other Events  Interactive Data
05/15/2023	10-Q	Quarterly Report for the period ended March 31, 2023
05/10/2023	S-1/A	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
04/13/2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Nov-30-16	Dec-31-15
Revenues	0.0	0.0	0.0	0.1	0.0	0.0	1.6	3.3
Revenue growth			-100.0%	405.6%	-26.2%			7517.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.4
Gross profit	0.0	0.0	0.0	0.1	0.0	0.0	0.8	1.8
Gross margin				75.1%	65.7%	44.2%	53.8%	56.1%
Sales and marketing	0.0		0.0	0.0	0.0	0.1	0.3	0.8
Research and development	0.7	0.7	0.4
General and administrative	1.5	1.3	0.5	0.6	0.9	1.1
EBITA	-2.1	-2.0	-0.9	-0.2	0.2	-1.8	-0.4	-0.7
EBITA margin				-151.2%	609.3%	-4699.6%	-28.3%	-21.5%
Amortization of intangibles	0.0	0.0	0.0	0.1	0.2	0.2	0.1	0.0
EBIT	-2.1	-2.0	-0.9	-0.3	-0.1	-2.0	-0.5	-0.7
EBIT margin				-195.1%	-218.6%	-5277.4%	-32.3%	-22.8%
Pre-tax income	-2.9	-3.0	-1.3	-3.3	-2.3	-3.8	-0.6	-0.8
Income taxes	0.0	0.0	0.0	-0.2	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	7.2%			0.0%	0.0%
Earnings from continuing ops	-2.9	-3.0	-1.3	-3.3	-2.3	-3.8	-0.6	-0.8
Earnings from discontinued ops				0.3	-0.3	-0.4
Net income	-2.9	-3.0	-1.3	-3.1	-2.6	-4.3	-0.6	-0.8
Net margin				-2145.3%	-9243.2%	-11061.2%	-40.7%	-24.4%

Diluted EPS	($0.08)	($0.08)	($0.17)	($0.04)	($0.04)	($0.08)	($0.06)	($0.08)
Shares outstanding (diluted)	37.4	36.4	7.4	81.3	65.1	47.1	10.0	9.8

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.